POLYPEPTIDES AND USES THEREOF AS A DRUG FOR TREATMENT OF AUTOIMMUNE DISORDERS

• US 20190309044A1
• Filed: 07/17/2018
• Published: 10/10/2019
• Est. Priority Date: 05/14/2017
• Status: Abandoned Application

• Current Assignee: Compugen Ltd
• Original Assignee: Compugen Ltd
• Inventors: HECHT, Iris, PODOJIL, Joseph R., MILLER, I, Stephen D., ROTMAN, Galit
• Application Number:
  US15/979,097
• Publication Number:
  US 20190309044A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/507 Comprising a combination of two or more separate antibodies
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/1774 Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
• CPC Class Codes: A61K 38/1793 for cytokines; for lymphokines; for interferons
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: C07K 14/70503 Immunoglobulin superfamily
• CPC Class Codes: C07K 14/7151 for tumor necrosis factor [TNF], for lymphotoxin [LT]
• CPC Class Codes: C07K 16/22 against growth factors ; against growth regulators
• CPC Class Codes: C07K 16/241 Tumor Necrosis Factors
• CPC Class Codes: C07K 16/244 Interleukins [IL]
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 2317/52 Constant or Fc region; Isotype
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• CPC Class Codes: C07K 2319/32 fusions with soluble part of a cell surface receptor, "decoy receptors"
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

This invention, in at least some embodiments, relates to a protein C1ORF32 and its variants and fragments and fusion proteins thereof, and methods of use thereof for immunotherapy, and drug development, including but not limited to as immune modulators and for immune therapy, including for autoimmune disorders and including for inducing tolerance to a specific antigen.

Claims

1. A method for treating a mammal in need of treatment thereof for an autoimmune disease, comprising administering to the mammal an inhibitor of the TNF (tumor necrosis factor) pathway to treat the autoimmune disease;

if manifestation of the autoimmune disease in the subject is not at least ameliorated by administering the inhibitor of the TNF pathway, administering an isolated polypeptide comprising a protein having an amino acid sequence according to any of SEQ ID NOs;

6-41, to treat the autoimmune disease.

2. The method of claim 1, wherein said isolated polypeptide comprises said protein having an amino acid sequence according to any of SEQ ID NOs:

6-41 fused to a human IgG1 Fc having an amino acid sequence set forth in any one of SEQ ID NOs;

45, 46, 47 or 65.

3. The method of claim 2 wherein said isolated polypeptide has an amino acid sequence as set forth in SEQ ID NO:

43.

4. The method of claim 1, wherein said isolated polypeptide has an amino acid sequence as set forth in SEQ ID NO:

26.

5. The method of claim 1, wherein said isolated polypeptide is administered in an amount that is from 0.1 to 100 mg/kg weight of a subject.

6. The method of claim 5, wherein said isolated polypeptide is administered in an amount that is from 0.1 to 20 mg/kg weight of a subject.

7. The method of claim 6, wherein said isolated polypeptide is administered in an amount that is from 10 to 15 mg/kg weight of a subject.

8. The method of claim 1, wherein the inhibitor of the TNF pathway is selected from the group consisting of an anti TNF antibody and a TNF receptor fusion protein.

9. The method of claim 8 wherein said anti TNF antibody is selected from the group consisting of infliximab, adalimumab, certolizumab pegol, and golimumab.

10. The method of claim 8 wherein said fusion protein is etanercept.

11. The method of claim 1, wherein said immune related disease is selected from the group consisting of psoriasis;

rheumatoid arthritis;

inflammatory bowel disease, ulcerative colitis;

Crohn'"'"'s disease, ankylosing spondylitis (AS), psoriatic arthritis, Plaque Psoriasis, juvenile idiopathic arthritis, Behç

et'"'"'s disease, non-infectious ocular inflammation, pyoderma gangrenosum and hidradenitis suppurativa.

12. The method of claim 11, wherein rheumatoid arthritis comprises one or more of rheumatoid arthritis, gout and pseudo-gout, juvenile idiopathic arthritis, juvenile rheumatoid arthritis, Still'"'"'s disease, ankylosing spondylitis, rheumatoid vasculitis and conditions related to rheumatoid arthritis.

13. The method of claim 12, wherein said conditions relating to rheumatoid arthritis include osteoarthritis, sarcoidosis, Henoch-Schö

nlein purpura, psoriatic arthritis, reactive arthritis, spondyloarthropathy, septic arthritis, haemochromatosis, hepatitis, vasculitis, Wegener'"'"'s granulomatosis, Lyme disease, familial mediterranean fever, hyperimmunoglobulinemia D with recurrent fever, TNF receptor associated periodic syndrome, and enteropathic arthritis associated with inflammatory bowel disease.

14. The method of claim 12, wherein said treatment reduces or at least slows development of rheumatoid arthritis symptoms including one or more of inflammation, fatigue, joint pain, joint tenderness, joint swelling, joint redness, joint warmth, joint stiffness, loss of joint range of motion, affecting more than one joint (polyarthritis), limping or joint deformity, or a combination thereof.

15. The method of claim 11, wherein inflammatory bowel disease comprises one or more of inflammatory bowel disease Crohn'"'"'s disease, ulcerative colitis (UC), collagenous colitis, lymphocytic colitis, ischaemic colitis, diversion colitis, Behç

et'"'"'s disease, or indeterminate colitis.

16. The method of claim 11, wherein psoriasis comprises one or more of psoriasis, nonpustular psoriasis including psoriasis vulgaris and psoriatic erythroderma (erythrodermic psoriasis), Plaque Psoriasis, pustular psoriasis including generalized pustular psoriasis (pustular psoriasis of von Zumbusch), pustulosis palmaris et plantaris (persistent palmoplantar pustulosis, pustular psoriasis of the Barber type, pustular psoriasis of the extremities), annular pustular psoriasis, acrodermatitis continua, impetigo herpetiformis and conditions relating to psoriasis.

17. The method of claim 16 wherein said conditions relating to psoriasis include drug-induced psoriasis, inverse psoriasis, napkin psoriasis, seborrheic-like psoriasis, guttate psoriasis, nail psoriasis, psoriatic arthritis.

18. The method of claim 16, wherein treatment reduces or at least slow development of overt symptoms of psoriasis, including one or more of red patches of skin covered with silvery scales;

small scaling spots;

dry, cracked skin that may bleed;

itching, burning or soreness;

thickened, pitted or ridged nails;

or swollen and stiff joints;

or a combination thereof.

19. A method for treating a mammal in need of treatment for rheumatoid arthritis, comprising determining that the mammal did not respond to a previous rheumatoid arthritis treatment;

and administering to the mammal an isolated polypeptide comprising a protein having an amino acid sequence according to any of SEQ ID NOs;

26 or 43 in a dosage in a range of from 10-15 mg/kg of a weight of the mammal.

20. The method of claim 19, wherein said previous rheumatoid arthritis treatment comprises one or more of a TNF blocker or CTLA4-Ig.

21. The method of claim 20, wherein said TNF blocker is selected from the group consisting of infliximab, adalimumab, Certolizumab pegol, Golimumab and etanercept or biosimilars of these drugs.

22. The method of claim 19, wherein the mammal that did not respond to a previous rheumatoid arthritis treatment exhibited a primary non-response.

23. The method of claim 19, wherein the mammal that did not respond to a previous rheumatoid arthritis treatment exhibited a secondary non-response.

24. The method of claim 19, wherein said isolated polypeptide comprises an amino acid sequence according to SEQ ID NO:

43.

25. The method of claim 19, wherein said administering decreases TNFα

secretion.

26. A method for treating a mammal in need of treatment thereof for an autoimmune disease, comprising administering to the mammal an inhibitor of the TNF pathway to treat the autoimmune disease;

determining that manifestation of the autoimmune disease in the subject is at least ameliorated by administering the inhibitor of the TNF pathway;

after a period of time has relapsed, determining that expression of the autoimmune disease in the subject is no longer at least ameliorated by administering the inhibitor of the TNF pathway; and

administering an isolated polypeptide comprising a protein having an amino acid sequence according to any of SEQ ID NOs;

6-41, to treat the autoimmune disease.

27. The method of claim 26, wherein said isolated polypeptide comprises an amino acid sequence as set forth in SEQ ID NO:

26.

28. The method of claim 27, wherein said isolated polypeptide comprises a fusion protein having an amino acid sequence as set forth in SEQ ID NO:

43.

29. The method of claim 27, further comprising administering a TNF-blocker in combination with said isolated polypeptide.

30. The method of claim 29, wherein said TNF blocker is selected from the group consisting of infliximab, adalimumab, Certolizumab pegol, Golimumab and etanercept or biosimilars of these drugs.

31. The method of claim 27, further comprising administering a TNF-blocker followed by administration of said isolated polypeptide.

32. The method of claim 31, wherein said TNF blocker is selected from the group consisting of infliximab, adalimumab, Certolizumab pegol, Golimumab and etanercept or biosimilars of these drugs.